Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes. In a court filing on ...

The professional services industry has seen amazing growth in the past few years, buoyed by digital transformation. But as firms aim for more growth, they’ll need to step up the pace of innovation.

Next: Access Our New, Shockingly Simple 'Alert System' RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...